bioMérieux S.A.
BMXMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.53B
Close$
$62.75
33.9% downside
Current Fair Value
33.9% downsideOvervalued by 33.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.53 Billion |
|---|---|
| Enterprise Value | $12.30 Billion |
| Annual dividend | $1.13 |
| Dividend yield | 1.08% |
| Earnings per Share | $3.37 |
| Beta | 0.57 |
| Outstanding Shares | 117,760,000 |
Return
| Return on Equity | 19.51% |
|---|---|
| Return on Assets | 14.73% |
| Return on Invested Capital | 24.93% |
Valuation & Multiples
| P/E Ratio | 23.03 |
|---|---|
| PEG | 56.95 |
| Price to Sales | 1.4 |
| Price to Book Ratio | 2.64 |
| Enterprise Value to Revenue | 1.52 |
| Enterprise Value to EBIT | 10.81 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 28, 2026
EPS Estimate
$2.32
Consensus analyst estimateRevenue Estimate
$2.21 B
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$2.74
Consensus analyst estimateRevenue Estimate
$2.43 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About bioMérieux S.A.
14,894 employees
CEO: Pierre Boulud
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems...